Introduction
Therapeutic anticoagulation has been traditionally performed with a limited set of anticoagulant drugs, of which the vitamin K antagonists (VKA) and heparinoids (unfractionated heparin and low molecular weight heparin variants) are the most important. Many years' experience of indirect inhibitors such as low molecular weight heparins and fondaparinux have shown factor Xa inhibition to be an effective anticoagulant strategy [1, 2] . However, these drugs have two important shortcomings; they require parenteral administration and are dependent on antithrombin, rendering them unable to inhibit factor Xa in the prothrombinase complex [3] . The first synthetic direct acting compound licensed for treatment of patients was rivaroxaban. Apixaban (Eliquis ® ), from Bristol Myers Squibb (Princeton, NJ, USA), is one of the newest oral direct Xa inhibitors, with a molecular weight of 459.5, an inhibitor constant, Ki, of 0.08 nM for human Xa and with greater than 30,000-fold selectivity over thrombin and other coagulation enzymes [4] . Apixaban is currently approved for stroke prophylaxis in patients with non-valvular atrial fibrillation and as an alternative to heparins for thromboprophylaxis after hip and knee replacements [5] . Phase III clinical trials have recently shown an antithrombotic effect non-inferior to warfarin in acute venous thromboembolism and significantly fewer bleeding complications [6, 7] . The new oral anticoagulants (NOACs) have an advantage over VKAs in that the effect does not need to be monitored with laboratory analyses. However, as the drugs are, at least in part, excreted by the kidneys and/or metabolized by the liver, it may be necessary to assess the anticoagulant effect with a specific test to avoid drug accumulation in some patients [8] . Other clinical situations in which testing can be considered are in emergency situations such as major bleeds or preoperative preparation. According to the manufacturer of apixaban the effects are small and variable on common coagulation assays. Therefore, the prothrombin time (PT) and activated partial thromboplastine time (APTT) should not be used to evaluate the pharmacodynamic effect of the drug. However, there is also a need to know what general effects apixaban might have on PT and APTT assays as they are widely available and routinely performed laboratory tests. Another aspect is whether it is possible to conduct a thrombophilia investigation during apixaban treatment. There are only limited reports on the pharmacokinetic and pharmacodynamic profiles of apixaban [7] [8] [9] [10] , including one, more extensive in vitro study of the effects on routine and more specialized coagulation assays [9] and one very recent study that investigated the effects of various APTT and PT reagents together with an evaluation of three different anti-Xa assays [10] . Both studies utilized pooled normal plasma spiked with apixaban. In the current study, we have used plasma samples from ten healthy individuals spiked with the pure apixaban substance to investigate the anticoagulant activities over a wide concentration.. The effects on common routine coagulation and analyses in the thrombophilia investigation have been studied as has the inter-individual variation in the effect.
Material and Methods

Study design
A working group, representing the coagulation laboratories at four Swedish university hospitals (Gothenburg, Linköping, Malmö and Stockholm), undertook the task to investigate the effects of apixaban on common coagulation assays. The study design involved a similar approach as the same working group used to investigate the in vitro effects of dabigatran [11] and rivaroxaban [12] . In brief, plasma samples from 10 different healthy individuals were spiked with apixaban at 10 different concentrations and aliquots were investigated at the four participating laboratories. All assays were divided between the participants, i.e. one lab investigated the effects on the different APTT reagents and another lab ran all the PT assays etc. As the preliminary results indicated that apixaban had quite different in vitro effects compared to the previously investigated drug rivaroxaban additional tests and direct comparisons between the drugs were performed. These included lupus anticoagulant assay and a home-made APTT with varying phospholipid concentrations. The selected plasma concentration interval was based on the expected concentrations obtained from published doseranging studies [7, 13, 14] . In the APPRAISE-1 study [15] on treatment of acute coronary syndrome, 2.5 mg and 10 mg twice-daily were used and resulted in a peak concentration of 68 (38/98; 5 th /95 th percentile) and 267 µg/L (122/412 µg/L; 5 th /95 th percentile), respectively [7] . The corresponding trough concentrations were 57 (18/97; 5 th /95 th percentile) and 221 µg/L (30/412; 5 th /95 th percentile), respectively. A twice-daily dose of 5 mg apixaban has been proposed as therapeutic strategy for stroke prophylaxis in patients with non-valvular atrial fibrillation. Plasma concentration profiles during different apixaban dosage regimens has been calculated from the results of a phase III trial [16] , and suggested that 5 mg twicedaily would result in a median trough concentration of 107 µg/L (56/203 µg/L; 10th/90th percentile). Based on these data and to facilitate comparison with our previous report on rivaroxaban [12] , we decided to highlight our results from the APTT and PT analyses with a maximum concentration of 200 µg/L and a trough concentration at 50 µg/L. In our study, we included up to 5-fold higher concentrations (1,000 µg/L) than the expected peak level, which would simulate a result of drug accumulation.
Materials
Apixaban was provided from the manufacturer, Bristol Myers Squibb; Rivaroxaban was provided from the manufacturer Bayer Schering Pharma AG. Stock preparations were made by dissolving the drugs in 100 % dimethyl sulphoxide (DMSO, Merck, Darmstadt, Germany). The evacuated blood collection tube system was from BD (Franklin Lakes, NJ, US). A phospholipid mixture, used for a local APTT method, containing phosphatidyl choline (42 %), phosphatidyl serine (28 %) and sphingomyelin (30 %) was purchased from Rossix AB (Mölndal, Sweden).
Production of plasma samples and apixaban calibrator
Human blood from 10 adult healthy volunteers, both men and women (five of each gender), was collected in evacuated plastic tubes containing 1:10 volume of 0.109 mol/L tri-sodium citrate as anticoagulant. Ten tubes, in total 50 mL citrated blood, were obtained from each individual. The tubes were centrifuged at 2,000 x g for 20 min, and the platelet-poor plasma from each individual was pooled and stored frozen at -70˚C. The plasma was thawed in a 37 ˚C water bath for 15 min, divided into 20 aliquots of 1.0 mL each, "spiked" with apixaban to final concentrations ranging from 0.0 to 1,000 µg/L and then stored at -70˚C until they were transported on dry ice to the participating laboratories for analysis.
Pooled normal plasma (n=45 healthy donors) was used to produce a calibrator set, containing 0, 25, 50, 100, 200 and 400 µg/L apixaban, for the anti-Xa assays that was used to quantitate the amount of apixaban in the individual plasma samples.
Pooled plasma, spiked with apixaban or rivaroxaban, was also used to evaluate the effects on additional tests involving lupus anticoagulant and an APTT assay with varying phospholipid content. All samples and calibrators were prepared so that the final DMSO concentration of became 1 % (v/v), irrespective of the drug concentration.
Routine coagulation analyses
The activated partial thromboplastin time (APTT) was assayed using 5 different Assays to assess protein S in plasma involved Coamatic Protein S free (Chromogenix), which measures free protein S antigen and two clot-based assays:
Protein S Ac (Siemens) and Staclot Protein S (Stago). The Coamatic Protein S free and Protein S Ac assays were performed on the BCS-XP instrument, whereas the Staclot Protein S was run on the STA-R Evolution analyzer according to the manufacturer's instructions.
Anti-Xa assays used for quantitation of apixaban in plasma.
At the time of the study there were no commercial available assays or calibrators for apixaban measurements and the participating laboratories used their local anti-Xa method in clinical use for measuring rivaroxaban. The STA Liquid anti-Xa assay from Stago was used by two laboratories, in one case on the Sysmex CS2100i instrument and in the other on STA-R Evolution. The other two laboratories used the Coamatic Heparin reagent from Chromogenix on BCS-XP and ACLTop, respectively. Both assays are without addition of exogenous antithrombin, which otherwise could compromise the results [18] . A common calibrator set was used for all participants and was based on pooled normal plasma spiked with apixaban in concentrations between 0 -400 µg/L. Samples that exceeded the highest calibration concentration of 400 µg/L were diluted with pooled normal plasma and re-analyzed, and the results were multiplied by the dilution factor (1:2 or 1:4).
Other assays used for direct comparison between apixaban and rivaroxaban
The LA1 screening reagent and LA2 confirmation reagent (Siemens) were used as an integrated dilute Russell's viper venom time (dRVVT) test to evaluate and compare the effect of anti-Xa drugs rivaroxaban and apixaban. The test was performed on the BCS-XP instrument, and the result is expressed as an LA1/LA2 ratio. According to the manufacturer, a ratio between1.2 and 1.5 is considered weakly positive or border line, a ratio between 1.5 and 2.0 is classified as moderately positive, and a ratio above 2.0 is strongly positive. 
Results
The effects of increasing apixaban concentrations on the five different APTT reagents were similar non-linear and flat dose-response curves (Fig 1) . Assuming a peak concentration of 200 µg/L, the responses were within the reference interval of each reagent group for most samples. Even at the highest concentration of 1,000 µg/L, the APTT remained below the upper reference limit for several samples in each APTT reagent group. The effect on the APTT, expressed as the concentration required doubling the APTT (CT2), was calculated to be between 2,203 and 4,666 µg/L for the five different reagents (Table 1) , which is a relative 2.1-fold difference.
The inter-individual variability is reflected to the same extent over the entire measuring range, i.e. the individual dose-response curves did not cross each other, and the same plasma donor that expressed the shortest or the longest APTT did so for each apixaban concentration (not shown).
There was a linear dose-response effect on the nine different PT assays with a wide variation. There was, however, no clear difference in sensitivities for apixaban between Quick PT and Owren PT type reagents (Fig. 2) Table 2 ).
The antithrombin activity assay based on factor Xa inhibition (Innovance Antithrombin) increased with the apixaban concentration whereas the other assay (Stachrom ATIII), based on thrombin inhibition, were not affected (not shown).
Already at expected trough levels of apixaban, around 50-100 µg/L, the factor Xabased antithrombin level reached the upper measuring range of the assay. In some of the samples with a concentration of 200 µg/L and in all samples with higher concentrations, no quantitative value could be obtained.
Protein C levels measured with coagulation-based assays were affected to some extent by apixaban, whereas the chromogenic assays were not ( fig. 3) . The Staclot Protein C assay from Stago was more sensitive than the Siemens Protein C coag assay meaning that the Staclot protein C levels were overestimated to a greater extent compared to the Siemens assay. Expressed as an increase in the protein C activity per 100 µg/l of the drug, assuming a linear dose-response model, the Staclot Protein C displayed an incremental increase of 0.04 IU/ml per 100 µg/l apixaban. The Protein C coag assay was not affected at apixaban concentrations below 100 µg/L; at higher concentrations, the average increase was less than 0.02 IU/ml per 100 µg/L of the drug. The effects on an integrated dRVVT test, manufactured for detection of lupus anticoagulant, were evaluated with increasing concentrations of rivaroxaban or apixaban in pooled normal plasma. It was shown that rivaroxaban affected the LA1 reagent, with low phospholipid, to a greater extent than apixaban did, whereas with the phospholipid-rich LA2 reagent, the dose-response curves were similar for both Xa inhibitors ( fig. 5 ). This gave (false) positive lupus anticoagulant ratios at rivaroxaban concentrations of 100 µg/L and higher, whereas the lowest apixaban concentration that resulted in a weak positive ratio was 600 µg/L (not shown).
Discussion
Apixaban is an oral, direct FXa inhibitor that not only has the capacity to inactivate free FXa but also clot-associated FXa activity and the FXa that is part of the prothrombinase complex [19] . Thus, apixaban has the potential to down-regulate the coagulation processes very efficiently and therefore may interfere in many coagulation assays in which FXa activity has an impact on the results obtained.
We observed that APTT and PT assays were weakly sensitive in general, but that there were differences between assays, which have also been acknowledged by the manufacturer. APTT was within the reference range for most donor samples at 200 µg/L, and PT was not above reference range or only slightly above, in accordance with previous studies on samples from patients with acute coronary syndrome [7] and healthy volunteers [12] . The recent in vitro studies by Douxfils et al. [9] and GouinThibault et al. [10] showed similar low sensitivities with other reagents for PT and APTT, indicating that the relatively weak apixaban effect is generalizable to many screening assays of the coagulation system. Thus, a normal APTT or a normal PT does not exclude a peak concentration of apixaban and is of no use in estimating the concentration of apixaban. A strength of our study is that it show the inter-individual variation for the routine coagulation assays. The broad range in APTT for the 10 healthy individual at peak or 5 times peak concentration (Table 1) illustrates the difficulties in evaluating an individual APTT result during apixaban therapy. Another observation is that the concentrations needed to double APTT (CT2) were for most reagents a factor of 5-6 times higher than for rivaroxaban [12] . However, for one of the reagents, Actin FSL, the CT2-value was 11 times higher than for rivaroxaban [12] .
Apixaban had weak effects on the tested PT assays. At 200 µg/L only two reagents resulted in a mean INR that was above the upper reference limit of 1.2. Even at the highest apixaban concentration some samples were still in the normal range. We grouped the PT assays in Quick and Owren types as it was assumed that the Quick PT assays would be more sensitive compared to the Owren PT, which has previously been shown with the oral anticoagulants dabigatran [11] and rivaroxaban [12] . The basis for this assumption is the differences in plasma dilution that is 1:3 for Quick PT compared to 1:21 for the Owren PT and this renders the Owren PT assay being less susceptible to various interfering substances including lupus anticoagulant. However, we found that the least sensitive PT reagent was the Quick type Innovin. The reason for this insusceptibility is unknown. Two recent in vitro studies resulted in similar findings that Innovin was the least sensitive PT reagent [9, 10] . All PT assays were affected to a lesser extent by apixaban in comparison with rivaroxaban. The relative sensitivity, illustrated by the CT2 values, revealed that 2 -7 times higher concentrations of apixaban were needed to double the PT compared to rivaroxaban.
In line with this observation is a study performed with rabbits that showed that rivaroxaban prolonged the APTT and PT more than apixaban [20] .
The effect on the dRVVT test was also less than expected given the fact that rivaroxaban can result in false positive lupus anticoagulant results [21 -23] . The dose-response curves in Figure 5 indicated that rivaroxaban and apixaban differed more in the LA1 screening test with limited phospholipid compared with the LA2 reagent that contained more phospholipid. Our observation is made with a single LAreagent and the results must be interpreted with caution but similar dose-dependent and equal effects on the screen and confirm tests, with low and high phospholipid content, has been reported for apixaban with two other lupus anticoagulant assays [9] . Thus, under therapeutic concentrations with apixaban, it may be possible that the dRVVT test will not give the false positive results shown with rivaroxaban. The reason for this discrepancy might be different sensitivities to the phospholipid content in the reagents. This was supported by our experiment based on the APTT with varying concentrations of added phospholipids that showed that the clotting time in samples containing apixaban were unaffected whereas coagulation times were dependent on the phospholipid contents in samples with rivaroxaban.
There is no obvious explanation for the differences between these two direct factor Xa inhibitors. As the molecular weight is similar -459.5 Da for apixaban [4] and 436 Da for rivaroxaban [24] -the molar concentration is very similar at the same mass concentration. The inhibitor constant, Ki, which is an indicator how potent an inhibitor is, for human factor Xa is lower for apixaban than for rivaroxaban, 0.08 nM and f 0.4 nM, respectively. This means that apixaban is slightly more potent in inhibiting Xa compared to rivaroxaban and cannot explain the observed differences in vitro. Both drugs have a >10,000-fold greater selectivity for factor Xa than for other serine proteases [4, 24] . Thus the difference in effects on APTT and PT between rivaroxaban and apixaban remains to be explained although our results suggest that the phospholipids in the investigated reagents seem to play a role. We would like to stress that this is an in vitro observation only, and there is no relation between these kind of effects and clinical effects for any of the new oral anticoagulants.
Chromogenic anti-Xa assays are the standard methodology for measuring the concentrations of indirect and direct Xa inhibitors. Two different assays were used on two different instruments for each reagent type with a programming recommended by the manufacturer for measuring the direct Xa inhibitor rivaroxaban. In the absence of a commercially available calibrator, the participating laboratories used identical sets of apixaban calibrators that were prepared by spiking the drug into pooled normal plasma. There were linear relationships between the expected and observed anti-Xa activities with good correlation for all combinations. Furthermore, equivalence expressed as the average recovery in percentage, was close to 100 % (range 95 -103 %), indicating that the anti-Xa assays used are suited to measuring apixaban when a drug-specific calibrator is used.
In conclusion, the APTT and PT are not useful for measuring the plasma concentration of apixaban, not even to obtain a crude estimate, unless the locally used assays are tested and validated for the effect. If the aim is to measure the pharmacodynamic effect of apixaban, more specific assays, preferably based on factor Xa inhibition, should be used. Furthermore, a useful laboratory screening for thrombophilia cannot be performed during apixaban therapy without knowledge of the influence on the locally used assays. The results obtained in our study will facilitate for laboratories to adequately estimate the effect of the drug on common coagulation assays. Table 3 . Determination of apixaban with chromogenic anti-Xa assays. 2) Recovery is calculated as the (measured value/expected value *100), and the reported average is the mean for all eight concentrations between 25 and 1,000 µg/L. 
